Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718166 | 0.86 | LMNA (0.66) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL4713929 | 0.85 | GRIN2D (0.54) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL4717867 | 0.75 | OPRM1 (0.47) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL4219496 | 0.72 | GRIN2D (0.70) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL22530506 | 0.72 | LMNA (0.44) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL3893851 | 0.72 | LMNA (0.63) | LMNAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL1548732 | 0.71 | KMT2A (0.53) | LMNAALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9748193 | 0.70 | MEN1 (0.40) | ALDH1A1MEN1KMT2AHTTGAA | |
| SCHEMBL1548396 | 0.70 | MEN1 (0.56) | LMNAALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4228209 | 0.68 | KMT2A (0.60) | ALDH1A1MEN1KMT2ASMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904439-A2 | SPHINGOSINE KINASE INHIBITORS | Apogee Biothechnology Corporation (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | claimed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-20200113881-A1 | METHOD FOR TREATING CANCER WITH COMBINATION THERAPY | REDHILL BIOPHARMA LTD (IL) | 2020-04-16 | — | — | US | disclosed |
| EP-1904439-A2 | SPHINGOSINE KINASE INHIBITORS | Apogee Biothechnology Corporation (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | LMNA 3895/4885ALDH1A1 31/4885MEN1 3237/4885 |
| US-20200113881-A1 | METHOD FOR TREATING CANCER WITH COMBINATION THERAPY | TPMT, KRAS, SDHA | LMNA 3895/4885ALDH1A1 31/4885MEN1 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.